Drug Profile
BMS 181184
Alternative Names: BMY 28762; BMY 28801; BMY 28864Latest Information Update: 16 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class AIDS vaccines; Antifungals; Antivirals; Fungal vaccines
- Mechanism of Action Cell membrane modulators; HIV envelope protein gp120 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections; Mycoses; Pneumocystis pneumonia
Most Recent Events
- 27 Feb 2001 No-Development-Reported for HIV infections treatment in Japan (Parenteral)
- 27 Feb 2001 No-Development-Reported for HIV infections treatment in United Kingdom (Parenteral)
- 27 Feb 2001 No-Development-Reported for HIV infections treatment in USA (Parenteral)